Zenlabs Ethica Posts Major Loss After RBI Cancels NBFC License

OTHER
Whalesbook Logo
AuthorIshaan Verma|Published at:
Zenlabs Ethica Posts Major Loss After RBI Cancels NBFC License
Overview

Zenlabs Ethica Limited has reported a sharp net loss of ₹200.76 Lakhs for the quarter ended December 31, 2025, a stark reversal from a profit in the prior year. The loss was primarily driven by an exceptional write-off of ₹207.81 Lakhs, a direct consequence of the Reserve Bank of India cancelling the company's NBFC registration on November 7, 2025. Revenue from operations declined 2.3% year-on-year for the quarter and 5.5% for the nine months, signalling significant operational challenges.

📉 The Financial Deep Dive

Zenlabs Ethica Limited has unveiled its unaudited financial results for the quarter and nine months ending December 31, 2025, revealing a significant financial downturn and operational upheaval.

The Numbers:

  • Q3 FY26 Performance: Revenue from operations stood at ₹1,242.78 Lakhs, marking a 2.3% decrease year-on-year from ₹1,272.29 Lakhs in Q3 FY25. Profit before exceptional items saw a substantial 49.4% drop to ₹6.35 Lakhs from ₹12.54 Lakhs in the previous year's quarter.
  • Exceptional Item & Net Loss: A pivotal factor in the quarter's results was an exceptional write-off of ₹207.81 Lakhs. This write-off, attributed to investments and other loans/advances, directly resulted from the Reserve Bank of India's order on November 7, 2025, cancelling the company's Non-Banking Financial Company (NBFC) registration. Consequently, Zenlabs Ethica reported a net loss of ₹200.76 Lakhs for Q3 FY26, a stark contrast to the profit of ₹8.51 Lakhs in Q3 FY25.
  • Earnings Per Share (EPS): The basic and diluted EPS turned negative, standing at ₹(3.08) per share for the quarter, down from ₹0.13 in the prior year.
  • Nine-Month Performance (9M FY26): Revenue from operations declined by 5.5% year-on-year to ₹3,633.84 Lakhs from ₹3,843.71 Lakhs. Profit before exceptional items fell 31.8% to ₹18.61 Lakhs from ₹27.29 Lakhs. The same exceptional item impacted the nine-month results, leading to a net loss of ₹193.67 Lakhs, compared to a profit of ₹17.86 Lakhs in the corresponding period of FY25. The nine-month EPS was ₹(2.98) per share, down from ₹0.27.

The Quality:

The company's profitability has been severely eroded by an exceptional charge related to the cancellation of its NBFC license. This write-off wiped out any operating profit and pushed the company into a significant net loss for both the quarter and the nine-month period. The revenue decline further exacerbates the challenging financial picture.

Risks & Outlook:

The primary and most significant risk for Zenlabs Ethica is the cancellation of its NBFC registration by the RBI. This regulatory action fundamentally alters the company's operational scope and financial structure, necessitating a complete re-evaluation of its business model. The write-off of investments and loans/advances indicates potential difficulties in realizing assets associated with its former NBFC activities. The company operates in pharmaceutical formulation trading, and it remains to be seen how this regulatory setback will impact its ability to conduct business in its primary segment.

Furthermore, the recent resignation of Ms. Manju Bala as Company Secretary and Compliance Officer, with Mr. Amit Kumar appointed to the role, introduces an element of management transition and governance considerations that investors will monitor closely.

The forward view for Zenlabs Ethica is highly uncertain, contingent on its ability to navigate the aftermath of the NBFC license cancellation and potentially restructure its operations to focus solely on its pharmaceutical trading business, while managing the financial impact of the write-off.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.